Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
about
A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicityGastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategiesA comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an exampleSafe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksIndividualized cost-effectiveness analysis.The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review.Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis.Cost-effectiveness of pharmaceutical management for osteoarthritis pain: a systematic review of the literature and recommendations for future economic evaluation.Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidanceThe cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi ArabiaCost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin.Assessing the external validity of algorithms to estimate EQ-5D-3L from the WOMAC.Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.Managing the adverse effects of nonsteroidal anti-inflammatory drugs.Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel.What you need to know when you prescribe a proton pump inhibitor.Premature discard of proton pump inhibitors: possible osteoporosis vs enhanced gastrointestinal bleed, adenocarcinoma efficacy.Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts.Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.Outpatient management of knee osteoarthritis.Economic evaluation of using a genetic test to direct breast cancer chemoprevention in white women with a previous breast biopsy.Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal CancerModelling the complete continuum of care using system dynamics: the case of osteoarthritis in AlbertaA fixed-dose combination of naproxen and esomeprazole magnesium has comparable upper gastrointestinal tolerability to celecoxib in patients with osteoarthritis of the knee: Results from two randomized, parallel-group, placebo-controlled trials
P2860
Q24615651-29D9C7B4-6F51-4492-ABFB-5DFE65C24DA9Q27026351-3BB046AF-390C-4919-9F29-AC759AEEC4BDQ28472098-7743F7E1-9734-4E2B-8DF8-9C4AF8A70890Q30629677-CC251271-EECA-49F8-8D4E-8B4876A28D4BQ33963712-F80297AD-9756-450B-AFC1-6FB5F016EC4FQ34347558-E934C16A-4483-4BEC-8828-53FFF86B0C90Q34384075-C1B3D824-D3EE-4EE7-A4DE-730413F43473Q34499039-D77E7115-0C24-49BA-B63A-52AF4002397FQ34591000-B5985336-50A4-442E-8FCB-189C38524D65Q34655792-C9E9CCEA-55D3-424A-87BD-349499A24307Q35743672-D1C75026-F78E-49DD-8AF4-9F8A8EBC2409Q36715136-DF48EA46-61BD-4F58-9FBF-1DECB3352258Q37311129-48E77395-71C5-43D8-A7DA-061552FB41F5Q37358250-A8C22889-FBD0-4EFD-B36B-5E2787B511B2Q37808208-915FE72D-E4E4-4CDB-A27F-F7205E264392Q37960540-49EEAAA6-D289-441C-B1C0-755FFFB075D7Q38127002-F7178A20-087B-4B2C-9752-4CE595430733Q41060355-46B5C541-2D24-4B5D-AAA3-ECDD9E97461BQ43055327-4991AB2B-1586-4884-AB55-8AB1D5BC910AQ44847410-4399A15D-F032-494E-907D-40465855B2A4Q45347178-A7564933-285F-4EA9-BB47-B0AC8A007BC6Q45402281-8E250A31-DF6F-4354-81D4-6AB0D3EF7AC9Q50460101-74D414DC-2EE9-45FA-A84B-9296CC750F42Q57152512-C0D46B14-C92C-4E28-910A-3B88BCE339C7Q57759101-101BA629-1EFB-43C6-B2F0-6542E22DE6BFQ58139133-1F9929AF-EDEE-4072-A444-D2CBC11EDF16
P2860
Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost effectiveness of COX 2 se ...... or people with osteoarthritis.
@en
Cost effectiveness of COX 2 se ...... or people with osteoarthritis.
@en-gb
Cost effectiveness of COX 2 se ...... or people with osteoarthritis.
@nl
type
label
Cost effectiveness of COX 2 se ...... or people with osteoarthritis.
@en
Cost effectiveness of COX 2 se ...... or people with osteoarthritis.
@en-gb
Cost effectiveness of COX 2 se ...... or people with osteoarthritis.
@nl
prefLabel
Cost effectiveness of COX 2 se ...... or people with osteoarthritis.
@en
Cost effectiveness of COX 2 se ...... or people with osteoarthritis.
@en-gb
Cost effectiveness of COX 2 se ...... or people with osteoarthritis.
@nl
P2093
P2860
P50
P356
P1433
P1476
Cost effectiveness of COX 2 se ...... or people with osteoarthritis.
@en
P2093
John Dickson
National Institute for Health ...... is Guideline Development Group
Rachel O'Mahony
Robert L Grant
P2860
P356
10.1136/BMJ.B2538
P407
P577
2009-07-14T00:00:00Z